Human parainfluenza virus type 2 (HPIV2) can result in severe respiratory illness in infants and young children. This study will test the safety of and immune response to an HPIV2 vaccine aimed at infants and children.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety, as determined by frequency of adverse events
Timeframe: Measured at baseline, for 11 days after vaccination, and at 1 month follow-up
Immunogenicity, as determined by ability to cause an immunological reaction and amount of antibody induced by the vaccine
Timeframe: Measured at baseline and at 1 month
Infectivity, as determined by amount of vaccine shed by each recipient
Timeframe: Measured at baseline, for 11 days after vaccination, and at 1 month follow-up